Erin Touchette currently serves as a Study Director II at Inotiv, where she plays a pivotal role in advancing infectious disease pharmacology research. With a robust background in the pharmaceuticals industry, Erin is recognized for her expertise in managing complex studies involving BSL-2 agents and...
Erin Touchette currently serves as a Study Director II at Inotiv, where she plays a pivotal role in advancing infectious disease pharmacology research. With a robust background in the pharmaceuticals industry, Erin is recognized for her expertise in managing complex studies involving BSL-2 agents and humanized liver mouse models. As the Scientific Lead of Infectious Disease Pharmacology, she is the primary point of contact for all related projects, ensuring the seamless delivery of pharmacology, pharmacokinetics-pharmacodynamics (PK-PD), and toxicology models.
Erin's strong foundation in public health, bolstered by her Master's degree from Saint Louis University, equips her with a unique perspective on the intersection of research and real-world applications. Her proficiency in data analysis and software documentation enhances her ability to oversee study monitoring and ensure compliance with biosafety regulations. Additionally, Erin's skills in utilizing advanced techniques such as real-time polymerase chain reaction (qPCR) contribute to the precision and reliability of experimental outcomes.
At Inotiv, Erin is actively involved in key projects that aim to develop innovative therapeutic strategies against infectious diseases. Her organizational skills and commitment to service work within a Contract Research Organization (CRO) setting enable her to effectively collaborate with multidisciplinary teams, driving projects from conception through to successful execution. With a keen focus on veterinary medicine and pharmacology, Erin Touchette continues to make significant contributions to the field, positioning herself as a leader in infectious disease research and development.
